Annual EBIT
$205.30 M
+$40.35 M+24.46%
31 December 2023
Summary:
BioMarin Pharmaceutical annual earnings before interest & taxes is currently $205.30 million, with the most recent change of +$40.35 million (+24.46%) on 31 December 2023. During the last 3 years, it has risen by +$226.82 million (+1054.15%). BMRN annual EBIT is now at all-time high.BMRN EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$137.41 M
+$1.70 M+1.25%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly earnings before interest & taxes is currently $137.41 million, with the most recent change of +$1.70 million (+1.25%) on 30 September 2024. Over the past year, it has increased by +$91.96 million (+202.34%). BMRN quarterly EBIT is now -0.42% below its all-time high of $137.99 million, reached on 31 March 2022.BMRN Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$407.04 M
+$91.96 M+29.19%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM earnings before interest & taxes is currently $407.04 million, with the most recent change of +$91.96 million (+29.19%) on 30 September 2024. Over the past year, it has increased by +$241.10 million (+145.28%). BMRN TTM EBIT is now at all-time high.BMRN TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.5% | +202.3% | +145.3% |
| 3 y3 years | +1054.2% | +424.9% | +1087.4% |
| 5 y5 years | +307.3% | +977.0% | +500.8% |
BMRN EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +438.8% | -0.4% | +317.0% | at high | +771.6% |
| 5 y | 5 years | at high | +307.3% | -0.4% | +317.0% | at high | +494.1% |
| alltime | all time | at high | +125.8% | -0.4% | +124.0% | at high | +151.2% |
BioMarin Pharmaceutical EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $137.41 M(+1.3%) | $407.04 M(+29.2%) |
| June 2024 | - | $135.71 M(+24.4%) | $315.08 M(+24.1%) |
| Mar 2024 | - | $109.09 M(+339.3%) | $253.94 M(+23.7%) |
| Dec 2023 | $205.30 M(+24.5%) | $24.83 M(-45.4%) | $205.30 M(+23.7%) |
| Sept 2023 | - | $45.45 M(-39.0%) | $165.95 M(+34.6%) |
| June 2023 | - | $74.56 M(+23.3%) | $123.28 M(+41.0%) |
| Mar 2023 | - | $60.46 M(-516.2%) | $87.42 M(-47.0%) |
| Dec 2022 | $164.95 M(-372.2%) | -$14.53 M(-623.4%) | $164.95 M(+42.0%) |
| Sept 2022 | - | $2.77 M(-92.8%) | $116.16 M(+63.4%) |
| June 2022 | - | $38.71 M(-71.9%) | $71.09 M(+41.2%) |
| Mar 2022 | - | $137.99 M(-317.9%) | $50.35 M(-183.1%) |
| Dec 2021 | -$60.61 M(+181.7%) | -$63.32 M(+49.7%) | -$60.61 M(+47.0%) |
| Sept 2021 | - | -$42.29 M(-335.3%) | -$41.23 M(-18.5%) |
| June 2021 | - | $17.97 M(-33.5%) | -$50.55 M(-51.0%) |
| Mar 2021 | - | $27.03 M(-161.5%) | -$103.27 M(+368.6%) |
| Dec 2020 | -$21.52 M(-70.7%) | -$43.94 M(-14.9%) | -$22.04 M(-229.5%) |
| Sept 2020 | - | -$51.62 M(+48.6%) | $17.02 M(-79.1%) |
| June 2020 | - | -$34.75 M(-132.1%) | $81.40 M(+1.0%) |
| Mar 2020 | - | $108.27 M(-2317.7%) | $80.61 M(-209.1%) |
| Dec 2019 | -$73.38 M(-25.9%) | -$4.88 M(-138.3%) | -$73.89 M(-27.2%) |
| Sept 2019 | - | $12.76 M(-135.9%) | -$101.56 M(-17.2%) |
| June 2019 | - | -$35.54 M(-23.1%) | -$122.60 M(+16.7%) |
| Mar 2019 | - | -$46.23 M(+42.0%) | -$105.03 M(+6.0%) |
| Dec 2018 | -$99.04 M(-3287.7%) | -$32.55 M(+292.6%) | -$99.04 M(+9359.5%) |
| Sept 2018 | - | -$8.29 M(-53.8%) | -$1.05 M(-71.2%) |
| June 2018 | - | -$17.96 M(-55.4%) | -$3.63 M(-83.5%) |
| Mar 2018 | - | -$40.25 M(-161.5%) | -$22.07 M(-810.2%) |
| Dec 2017 | $3.11 M(-100.4%) | $65.45 M(-701.8%) | $3.11 M(-102.1%) |
| Sept 2017 | - | -$10.88 M(-70.1%) | -$145.66 M(-24.3%) |
| June 2017 | - | -$36.39 M(+141.4%) | -$192.45 M(-73.6%) |
| Mar 2017 | - | -$15.07 M(-81.9%) | -$729.88 M(-8.2%) |
| Dec 2016 | -$794.92 M(+563.7%) | -$83.33 M(+44.5%) | -$794.92 M(+30.3%) |
| Sept 2016 | - | -$57.66 M(-90.0%) | -$610.12 M(-3.8%) |
| June 2016 | - | -$573.83 M(+616.3%) | -$634.28 M(+374.0%) |
| Mar 2016 | - | -$80.11 M(-178.9%) | -$133.81 M(+11.7%) |
| Dec 2015 | -$119.77 M(+30.8%) | $101.47 M(-224.0%) | -$119.77 M(-57.0%) |
| Sept 2015 | - | -$81.82 M(+11.5%) | -$278.62 M(+50.4%) |
| June 2015 | - | -$73.36 M(+11.0%) | -$185.29 M(+41.2%) |
| Mar 2015 | - | -$66.07 M(+15.2%) | -$131.26 M(+43.4%) |
| Dec 2014 | -$91.56 M(-45.2%) | -$57.37 M(-598.4%) | -$91.56 M(+5.6%) |
| Sept 2014 | - | $11.51 M(-159.5%) | -$86.70 M(-42.2%) |
| June 2014 | - | -$19.34 M(-26.6%) | -$150.06 M(-0.3%) |
| Mar 2014 | - | -$26.36 M(-49.8%) | -$150.48 M(-10.0%) |
| Dec 2013 | -$167.13 M(+49.8%) | -$52.51 M(+1.3%) | -$167.13 M(+2.1%) |
| Sept 2013 | - | -$51.85 M(+162.4%) | -$163.75 M(+34.4%) |
| June 2013 | - | -$19.76 M(-54.1%) | -$121.82 M(-8.1%) |
| Mar 2013 | - | -$43.01 M(-12.4%) | -$132.55 M(+18.8%) |
| Dec 2012 | -$111.60 M(+216.9%) | -$49.12 M(+395.0%) | -$111.60 M(+33.3%) |
| Sept 2012 | - | -$9.92 M(-67.5%) | -$83.71 M(-8.4%) |
| June 2012 | - | -$30.49 M(+38.2%) | -$91.35 M(+52.7%) |
| Mar 2012 | - | -$22.06 M(+3.9%) | -$59.83 M(+69.9%) |
| Dec 2011 | -$35.22 M | -$21.24 M(+20.9%) | -$35.22 M(+15.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$17.56 M(-1808.5%) | -$30.47 M(+109.9%) |
| June 2011 | - | $1.03 M(-59.8%) | -$14.52 M(+17.7%) |
| Mar 2011 | - | $2.56 M(-115.5%) | -$12.33 M(+15.6%) |
| Dec 2010 | -$10.67 M(-172.8%) | -$16.49 M(+924.3%) | -$10.67 M(-186.0%) |
| Sept 2010 | - | -$1.61 M(-150.1%) | $12.42 M(-49.3%) |
| June 2010 | - | $3.21 M(-23.8%) | $24.49 M(-11.0%) |
| Mar 2010 | - | $4.22 M(-36.1%) | $27.52 M(+87.8%) |
| Dec 2009 | $14.66 M(-70.6%) | $6.60 M(-37.0%) | $14.65 M(-62.1%) |
| Sept 2009 | - | $10.46 M(+67.8%) | $38.71 M(+15.8%) |
| June 2009 | - | $6.24 M(-172.1%) | $33.43 M(-5.1%) |
| Mar 2009 | - | -$8.65 M(-128.2%) | $35.23 M(-21.2%) |
| Dec 2008 | $49.82 M(-187.0%) | $30.65 M(+491.1%) | $44.70 M(+988.7%) |
| Sept 2008 | - | $5.19 M(-35.5%) | $4.11 M(-122.3%) |
| June 2008 | - | $8.04 M(+883.4%) | -$18.39 M(-54.1%) |
| Mar 2008 | - | $818.00 K(-108.2%) | -$40.03 M(-30.5%) |
| Dec 2007 | -$57.29 M(+132.2%) | -$9.94 M(-42.6%) | -$57.64 M(-2.7%) |
| Sept 2007 | - | -$17.31 M(+27.3%) | -$59.26 M(+28.6%) |
| June 2007 | - | -$13.60 M(-19.0%) | -$46.07 M(+36.3%) |
| Mar 2007 | - | -$16.79 M(+45.2%) | -$33.80 M(+37.0%) |
| Dec 2006 | -$24.67 M(-61.6%) | -$11.56 M(+180.9%) | -$24.67 M(-4.9%) |
| Sept 2006 | - | -$4.12 M(+207.9%) | -$25.94 M(-25.9%) |
| June 2006 | - | -$1.34 M(-82.5%) | -$34.99 M(-33.3%) |
| Mar 2006 | - | -$7.66 M(-40.3%) | -$52.43 M(-18.3%) |
| Dec 2005 | -$64.21 M(-56.6%) | -$12.83 M(-2.6%) | -$64.21 M(-52.4%) |
| Sept 2005 | - | -$13.17 M(-29.8%) | -$134.94 M(-9.1%) |
| June 2005 | - | -$18.77 M(-3.4%) | -$148.39 M(+0.3%) |
| Mar 2005 | - | -$19.44 M(-76.7%) | -$148.02 M(+0.1%) |
| Dec 2004 | -$147.91 M(+95.1%) | -$83.56 M(+213.9%) | -$147.91 M(+65.3%) |
| Sept 2004 | - | -$26.62 M(+44.7%) | -$89.47 M(+7.1%) |
| June 2004 | - | -$18.40 M(-4.8%) | -$83.52 M(+12.0%) |
| Mar 2004 | - | -$19.34 M(-23.0%) | -$74.59 M(-1.6%) |
| Dec 2003 | -$75.80 M(+12.1%) | -$25.11 M(+21.5%) | -$75.80 M(-1.5%) |
| Sept 2003 | - | -$20.67 M(+118.1%) | -$76.94 M(+7.9%) |
| June 2003 | - | -$9.48 M(-53.9%) | -$71.32 M(-4.7%) |
| Mar 2003 | - | -$20.54 M(-21.7%) | -$74.81 M(+10.6%) |
| Dec 2002 | -$67.62 M(+42.0%) | -$26.25 M(+74.5%) | -$67.62 M(+13.4%) |
| Sept 2002 | - | -$15.05 M(+16.0%) | -$59.61 M(+9.9%) |
| June 2002 | - | -$12.97 M(-2.8%) | -$54.24 M(+5.7%) |
| Mar 2002 | - | -$13.35 M(-26.8%) | -$51.29 M(+10.6%) |
| Dec 2001 | -$47.63 M(+33.5%) | -$18.24 M(+88.5%) | -$46.38 M(+13.6%) |
| Sept 2001 | - | -$9.67 M(-3.6%) | -$40.84 M(+3.6%) |
| June 2001 | - | -$10.03 M(+18.8%) | -$39.42 M(+7.8%) |
| Mar 2001 | - | -$8.44 M(-33.5%) | -$36.57 M(+2.5%) |
| Dec 2000 | -$35.67 M(+38.3%) | -$12.70 M(+54.0%) | -$35.67 M(+17.4%) |
| Sept 2000 | - | -$8.25 M(+14.7%) | -$30.38 M(+1.5%) |
| June 2000 | - | -$7.19 M(-4.7%) | -$29.93 M(+3.8%) |
| Mar 2000 | - | -$7.54 M(+1.9%) | -$28.84 M(+11.4%) |
| Dec 1999 | -$25.80 M(+100.0%) | -$7.40 M(-5.2%) | -$25.88 M(+40.0%) |
| Sept 1999 | - | -$7.80 M(+27.9%) | -$18.48 M(+73.0%) |
| June 1999 | - | -$6.10 M(+33.1%) | -$10.68 M(+133.1%) |
| Mar 1999 | - | -$4.58 M | -$4.58 M |
| Dec 1998 | -$12.90 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual earnings before interest & taxes?
- What is the all time high annual EBIT for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual EBIT year-on-year change?
- What is BioMarin Pharmaceutical quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly EBIT year-on-year change?
- What is BioMarin Pharmaceutical TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM EBIT year-on-year change?
What is BioMarin Pharmaceutical annual earnings before interest & taxes?
The current annual EBIT of BMRN is $205.30 M
What is the all time high annual EBIT for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual earnings before interest & taxes is $309.69 M
What is BioMarin Pharmaceutical annual EBIT year-on-year change?
Over the past year, BMRN annual earnings before interest & taxes has changed by +$40.35 M (+24.46%)
What is BioMarin Pharmaceutical quarterly earnings before interest & taxes?
The current quarterly EBIT of BMRN is $137.41 M
What is the all time high quarterly EBIT for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly earnings before interest & taxes is $137.99 M
What is BioMarin Pharmaceutical quarterly EBIT year-on-year change?
Over the past year, BMRN quarterly earnings before interest & taxes has changed by +$91.96 M (+202.34%)
What is BioMarin Pharmaceutical TTM earnings before interest & taxes?
The current TTM EBIT of BMRN is $407.04 M
What is the all time high TTM EBIT for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM earnings before interest & taxes is $407.04 M
What is BioMarin Pharmaceutical TTM EBIT year-on-year change?
Over the past year, BMRN TTM earnings before interest & taxes has changed by +$241.10 M (+145.28%)